BioSpace News Archive

The artificial joints and limbs market is expected to observe profitable growth across the forecast period of 2018-2026.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.

Biotage has managed to deal with the global challenges in the supply chain and ended 2021 with another sales record in the fourth quarter.

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m. ET.

Talaris Therapeutics, Inc. announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

IsoPlexis Corporation, the Superhuman Cell Company, announced the company will be participating in the following investor conferences.

Data from several new studies presented this week at the American Heart Association International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ai’s intelligent care coordination platform for stroke in real world settings across multiple commercial modules.

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced that company management will participate in Citi’s 2022 Immuno-Oncology Summit.

Hillstream BioPharma, Inc., a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced that company management will participate in the following upcoming investor conferences: